• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

sPAGM:通过整合基因和 miRNA 表达稳健的功能特征识别来推断亚通路活性,用于黑色素瘤预后。

sPAGM: inferring subpathway activity by integrating gene and miRNA expression-robust functional signature identification for melanoma prognoses.

机构信息

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.

出版信息

Sci Rep. 2017 Nov 10;7(1):15322. doi: 10.1038/s41598-017-15631-y.

DOI:10.1038/s41598-017-15631-y
PMID:29127397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5681640/
Abstract

MicroRNAs (miRNAs) regulate biological pathways by inhibiting gene expression. However, most current analytical methods fail to consider miRNAs, when inferring functional or pathway activities. In this study, we developed a model called sPAGM to infer subpathway activities by integrating gene and miRNA expressions. In this model, we reconstructed subpathway graphs by embedding miRNA components, and characterized subpathway activity (sPA) scores by simultaneously considering the expression levels of miRNAs and genes. The results showed that the sPA scores could distinguish different samples across tumor types, as well as samples between tumor and normal conditions. Moreover, the sPAGM model displayed more specificities than the entire pathway-based analyses. This model was applied to melanoma tumors to perform a prognosis analysis, which identified a robust 55-subpathway signature. By using The Cancer Genome Atlas and independently verified data sets, the subpathway-based signature significantly predicted the patients' prognoses, which were independent of clinical variables. In the prognostic performance comparison, the sPAGM model was superior to the gene-only and miRNA-only methods. Finally, we dissected the functional roles and interactions of components within the subpathway signature. Taken together, the sPAGM model provided a framework for inferring subpathway activities and identifying functional signatures for clinical applications.

摘要

微小 RNA(miRNAs)通过抑制基因表达来调节生物途径。然而,当推断功能或途径活性时,大多数当前的分析方法都无法考虑 miRNAs。在这项研究中,我们开发了一种称为 sPAGM 的模型,通过整合基因和 miRNA 表达来推断亚途径活性。在这个模型中,我们通过嵌入 miRNA 成分来重建亚途径图,并通过同时考虑 miRNA 和基因的表达水平来描述亚途径活性(sPA)评分。结果表明,sPA 评分可以区分不同肿瘤类型的样本,以及肿瘤和正常条件之间的样本。此外,sPAGM 模型比基于整个途径的分析具有更高的特异性。该模型应用于黑色素瘤肿瘤进行预后分析,确定了一个稳健的 55 个亚途径特征。通过使用癌症基因组图谱和独立验证的数据集,基于亚途径的特征显著预测了患者的预后,这与临床变量无关。在预后性能比较中,sPAGM 模型优于仅基于基因和仅基于 miRNA 的方法。最后,我们剖析了亚途径特征内组件的功能作用和相互作用。总之,sPAGM 模型为推断亚途径活性和识别临床应用的功能特征提供了一个框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/af423c0319c2/41598_2017_15631_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/9af827fa7529/41598_2017_15631_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/03cbeb256e42/41598_2017_15631_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/7b3a96f6a5ec/41598_2017_15631_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/bd6f4a9f5f30/41598_2017_15631_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/af423c0319c2/41598_2017_15631_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/9af827fa7529/41598_2017_15631_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/03cbeb256e42/41598_2017_15631_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/7b3a96f6a5ec/41598_2017_15631_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/bd6f4a9f5f30/41598_2017_15631_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46e0/5681640/af423c0319c2/41598_2017_15631_Fig5_HTML.jpg

相似文献

1
sPAGM: inferring subpathway activity by integrating gene and miRNA expression-robust functional signature identification for melanoma prognoses.sPAGM:通过整合基因和 miRNA 表达稳健的功能特征识别来推断亚通路活性,用于黑色素瘤预后。
Sci Rep. 2017 Nov 10;7(1):15322. doi: 10.1038/s41598-017-15631-y.
2
Identification of Subpathway Signatures For Ovarian Cancer Prognosis by Integrated Analyses of High-Throughput miRNA and mRNA Expression.通过高通量miRNA和mRNA表达综合分析鉴定卵巢癌预后的亚通路特征
Cell Physiol Biochem. 2017;44(4):1325-1336. doi: 10.1159/000485492. Epub 2017 Nov 29.
3
Identification of a robust subpathway-based signature for acute myeloid leukemia prognosis using an miRNA integrated strategy.基于 miRNA 整合策略的急性髓系白血病预后稳健子路径特征的鉴定。
PLoS One. 2018 Mar 23;13(3):e0194245. doi: 10.1371/journal.pone.0194245. eCollection 2018.
4
Integrating gene and lncRNA expression to infer subpathway activity for tumor analyses.整合基因和长链非编码RNA表达以推断肿瘤分析的亚通路活性。
Oncotarget. 2017 Nov 30;8(67):111433-111443. doi: 10.18632/oncotarget.22811. eCollection 2017 Dec 19.
5
Comprehensive analysis of mRNA-level and miRNA-level subpathway activities for identifying robust ovarian cancer prognostic signatures.综合分析 mRNA 水平和 miRNA 水平的亚通路活性,以鉴定稳健的卵巢癌预后标志物。
J Cell Mol Med. 2020 Feb;24(4):2582-2592. doi: 10.1111/jcmm.14968. Epub 2020 Jan 19.
6
PROONCOGENIC EFFECTS OF INHIBITING THE microRNA miR-106A IN SKIN MELANOMA CELLS IN VITRO.
Tsitologiia. 2016;58(9):679-87.
7
Subpathway-GMir: identifying miRNA-mediated metabolic subpathways by integrating condition-specific genes, microRNAs, and pathway topologies.子通路 - GMir:通过整合特定条件下的基因、微小RNA和通路拓扑结构来识别微小RNA介导的代谢子通路。
Oncotarget. 2015 Nov 17;6(36):39151-64. doi: 10.18632/oncotarget.5341.
8
Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.鉴定、回顾和系统交叉验证转移性黑色素瘤中的 microRNA 预后特征。
J Invest Dermatol. 2016 Jan;136(1):245-254. doi: 10.1038/JID.2015.355.
9
Analysis of melanoma-related microRNAs expression during the spontaneous regression of cutaneous melanomas in MeLiM pigs.MeLiM猪皮肤黑色素瘤自发消退过程中黑色素瘤相关微小RNA表达的分析。
Pigment Cell Melanoma Res. 2014 Jul;27(4):668-70. doi: 10.1111/pcmr.12243. Epub 2014 Apr 9.
10
Identification of a nine-miRNA signature for the prognosis of Uveal Melanoma.九miRNA 标志物用于葡萄膜黑色素瘤预后的鉴定。
Exp Eye Res. 2019 Mar;180:242-249. doi: 10.1016/j.exer.2019.01.004. Epub 2019 Jan 4.

引用本文的文献

1
Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses.通过全面综合分析鉴定胰腺导管腺癌稳健的功能子路径特征。
Cell Commun Signal. 2020 Mar 2;18(1):34. doi: 10.1186/s12964-020-0522-4.
2
Comprehensive analysis of mRNA-level and miRNA-level subpathway activities for identifying robust ovarian cancer prognostic signatures.综合分析 mRNA 水平和 miRNA 水平的亚通路活性,以鉴定稳健的卵巢癌预后标志物。
J Cell Mol Med. 2020 Feb;24(4):2582-2592. doi: 10.1111/jcmm.14968. Epub 2020 Jan 19.
3
Topologically inferring active miRNA-mediated subpathways toward precise cancer classification by directed random walk.

本文引用的文献

1
Ginkgol C17:1 inhibits tumor growth by blunting the EGF- PI3K/Akt signaling pathway.银杏内酯C17:1通过抑制表皮生长因子-磷脂酰肌醇-3激酶/蛋白激酶B信号通路来抑制肿瘤生长。
J Biomed Res. 2017 Jan 19;31(3):232-239. doi: 10.7555/JBR.31.20160039.
2
High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes.功能性细胞活性的高通量评估揭示疾病机制并预测相关临床结果。
Oncotarget. 2017 Jan 17;8(3):5160-5178. doi: 10.18632/oncotarget.14107.
3
An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.
通过有向随机游走对活跃 miRNA 介导的亚通路进行拓扑推断,实现精准癌症分类。
Mol Oncol. 2019 Oct;13(10):2211-2226. doi: 10.1002/1878-0261.12563. Epub 2019 Aug 27.
4
Unravelling miRNA regulation in yield of rice (Oryza sativa) based on differential network model.基于差异网络模型解析水稻(Oryza sativa)产量的 miRNA 调控。
Sci Rep. 2018 May 31;8(1):8498. doi: 10.1038/s41598-018-26438-w.
一种用于预测接受铂类化疗的肺腺癌患者反应并伴有一致生存获益的个体化特征。
Br J Cancer. 2016 Dec 6;115(12):1513-1519. doi: 10.1038/bjc.2016.370. Epub 2016 Nov 17.
4
Subpathway-GMir: identifying miRNA-mediated metabolic subpathways by integrating condition-specific genes, microRNAs, and pathway topologies.子通路 - GMir:通过整合特定条件下的基因、微小RNA和通路拓扑结构来识别微小RNA介导的代谢子通路。
Oncotarget. 2015 Nov 17;6(36):39151-64. doi: 10.18632/oncotarget.5341.
5
Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer.个性化通路分析揭示了散发性乳腺癌中DNA修复通路失调与染色体不稳定之间的关联。
Mol Oncol. 2016 Jan;10(1):179-93. doi: 10.1016/j.molonc.2015.09.007. Epub 2015 Sep 26.
6
Subpathway Analysis based on Signaling-Pathway Impact Analysis of Signaling Pathway.基于信号通路的信号通路影响分析的子通路分析
PLoS One. 2015 Jul 24;10(7):e0132813. doi: 10.1371/journal.pone.0132813. eCollection 2015.
7
Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma.基于通路的基因特征预测肺腺癌的临床结局。
Sci Rep. 2015 Jun 4;5:10979. doi: 10.1038/srep10979.
8
Individualized identification of disease-associated pathways with disrupted coordination of gene expression.通过基因表达失调进行疾病相关通路的个性化识别。
Brief Bioinform. 2016 Jan;17(1):78-87. doi: 10.1093/bib/bbv030. Epub 2015 May 27.
9
Pathway-based personalized analysis of breast cancer expression data.基于通路的乳腺癌表达数据个性化分析。
Mol Oncol. 2015 Aug;9(7):1471-83. doi: 10.1016/j.molonc.2015.04.006. Epub 2015 Apr 29.
10
Integrative analysis of lung development-cancer expression associations reveals the roles of signatures with inverse expression patterns.肺发育与癌症表达关联的综合分析揭示了具有相反表达模式的特征的作用。
Mol Biosyst. 2015 May;11(5):1271-84. doi: 10.1039/c5mb00061k.